Milestone Pharmaceuticals’ CARDAMYST: A Promising Buy with FDA Decision and Phase 3 Trial on Horizon
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research ...
Strategic Positioning and Financial Outlook: Ritu Baral’s Buy Rating on Milestone Pharmaceuticals Amidst Etripamil’s Promising Market Launch
TD Cowen analyst Ritu Baral maintained a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) yesterday and set a price ...
Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided ...